ClinicalTrials.gg
RecruitingNCT07059156Updated Jul 10, 2025

Multicenter Study of Combined Chemotherapy and Transplantation for Adult ALL

A Phase 2/3 interventional study of Induction Therapy Regimen and Pre-Treatment Regimen in Acute Lymphoblastic Leukemia, Adult, sponsored by Shanxi Bethune Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-07-10.

Sponsored by Shanxi Bethune Hospital · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 232 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in China — 113 open to participants now, 125 under way, 11 of them phase 3. Precursor Cell Lymphoblastic Leukemia-Lymphoma · China.

Planned enrollment
90th of 209
50 · median 45
Started
2025
with 27 others
Phase 2/3
11 of 232
4 open now
Primary completion
2027-06
later than 79 of 124 live
Registered
202nd of 232
by date

Among the 232 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in China, this one is the 90th largest by planned enrollment of the 209 interventional ones that give a count, is one of 28 that started in 2025, is one of 11 in phase 2/3, reaches primary completion later than 79 of the 124 other live ones, and was the 202nd registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 471 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

113 of the 232 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in China are open now. Recruiting first, the newest first:

107 more — sign in →

All 113 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 369 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (70%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 232 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in China, or all of them as a file.
02

Study summary

This study aims to evaluate an integrated treatment protocol for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia (Ph- ALL), combining induction chemotherapy, consolidation therapy, and allogeneic hematopoietic stem cell transplantation (allo-HSCT) to improve treatment efficacy and survival rates. The single-arm, open-label, multicenter study will enroll 50 newly diagnosed patients aged 18-60 years. The induction phase employs the VICP+VEN regimen (vindesine, idarubicin, cyclophosphamide, prednisone combined with venetoclax), followed by consolidation therapy with either Hyper-CVAD or CAM protocols, with eligible patients proceeding to allo-HSCT. Primary endpoints include disease-free survival (DFS) and complete remission (CR) rates, while secondary endpoints encompass relapse rate, overall survival (OS), and safety. Patients will be followed for 2 years with regular monitoring of minimal residual disease (MRD) and adverse events. The protocol is designed to reduce relapse risk through intensive therapy and transplantation, offering a potential cure for high-risk patients.The goal is to complete the entire treatment within 4 months after diagnosis.

Read the detailed description

1. Intervention Measures 1.1 Induction Therapy Regimen

VICP+VEN regimen:

  • Vindesine: 3 mg/m²/day (max 4 mg), administered on days 1, 8, 15, 22.
  • Idarubicin (IDA): 8 mg/m², days 1, 8, 15, 22.
  • Cyclophosphamide (CTX): 500 mg/m², days 7, 21.
  • Prednisone: 1 mg/kg/day, days 1-14; 0.5 mg/kg/day, days 15-28
  • Venetoclax (VEN) 8-day ramp-up: Day 1: 100 mg, Day 2: 200 mg, Days 3-8: 400 mg/day 1.2 Pre-Treatment Regimen

Indications for pre-treatment:

  • WBC ≥30×10⁹/L, or significant hepatosplenomegaly/lymphadenopathy.
  • Laboratory signs of tumor lysis syndrome (e.g., electrolyte abnormalities).

Pre-treatment protocol:

  • Glucocorticoids (e.g., prednisone or dexamethasone): Prednisone 1 mg/kg/day (PO/IV) for 3-5 days.
  • Optional addition of CTX: 200 mg/m²/day IV for 3-5 days. 1.3 Post-CR Treatment

Principles:

  1. MRD-positive or rising: Administer blinatumomab (CD19/CD3 bispecific antibody) for residual disease clearance, followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT).
  2. MRD-negative/unknown: Continue multi-agent chemotherapy ± blinatumomab consolidation. Allo-HSCT for patients with high-risk clinical/genetic features.

    1.4 Post-CR Consolidation Regimens

    ① Hyper-CVAD-B (Methotrexate/Cytarabine-based):

    • Methotrexate (MTX): 1 g/m² IV over 24h (Day 1) with urine alkalinization (pH >7.0) and leucovorin rescue.
    • Cytarabine (Ara-C): 1 g/m² IV q12h (Days 2-3; total 4 doses).
    • Dexamethasone: 40 mg/day (PO/IV, Days 1-4).
    • Cycle interval: 21-28 days (alternating with other regimens).

      • CAM Regimen:
    • CTX: 750 mg/m² IV (split over 2 days).
    • Ara-C: 75 mg/m²/dose (8 days; 1-2 doses/day IV; if once daily, administer 5 days/week × 2 weeks).
    • 6-MP: 50-75 mg/m²/day fasting (7-14 days PO). 1.5 Transplant-Eligible Subsequent Therapy
    • Allo-HSCT for eligible patients after induction.
    • Conditioning regimen: TBI-VP16-CY.
    • Donor priority: HLA-matched sibling donor (MSD), Matched unrelated donor (MUD), Haploidentical donor (Haplo). (Consider age/donor health status).

    1.6 Allo-HSCT Protocol 1.6.1 Conditioning Regimen (TBI-VP16-Cy/ATG):

    • TBI: 5 Gy (Days -7 to -6).
    • VP16: 10 mg/kg/day (Days -5 to -4).
    • CTX: 30 mg/kg/day (Days -3 to -2).
    • ATG: 7.5 mg/kg/day (Days -5 to -2). 1.6.2 GVHD Prophylaxis:
    • Basiliximab (anti-CD25 mAb): 50 mg (Days +1, +4).
    • Standard regimen: Cyclosporine (CsA): IV: 2 mg/kg/day (start Day -9; target level 150-250 μg/L). PO: 3-5 mg/kg/day BID (switch delayed until Day +10 if no aGVHD); Mycophenolate mofetil (MMF) + short-course methotrexate.

    1.7 Non-Transplant Maintenance Therapy

    Options:

    • Hyper-CVAD-B (Methotrexate/Cytarabine-based):

      • Methotrexate (MTX): 1 g/m² IV over 24h (Day 1) with urine alkalinization (pH >7.0) and leucovorin rescue.
      • Cytarabine (Ara-C): 1 g/m² IV q12h (Days 2-3; total 4 doses).
      • Dexamethasone: 40 mg/day (PO/IV, Days 1-4).
      • Cycle interval: 21-28 days (alternating with other regimens).

        • CAM Regimen:
      • CTX: 750 mg/m² IV (split over 2 days).
      • Ara-C: 75 mg/m²/dose (8 days; 1-2 doses/day IV; if once daily, administer 5 days/week × 2 weeks).
      • 6-MP: 50-75 mg/m²/day fasting (7-14 days PO).

        • Maintenance (6-MP/MTX alternating with V-Dex): 6-MP: 75 mg/m²/day at bedtime (Days 1-21); MTX: 20 mg/m² IM weekly × 3 weeks.*Adjust doses to maintain WBC \~3×10⁹/L, ANC 1.0-1.5×10⁹/L.*
03

Conditions studied

  • Acute Lymphoblastic Leukemia, Adult
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age: 18 to 60 years;
  2. Diagnosis must comply with the Chinese Guidelines for Diagnosis and Treatment of Adult Acute Lymphoblastic Leukemia (2024 Edition), requiring MICM (Morphology, Immunology, Cytogenetics, and Molecular genetics) integration and WHO 2022 (5th edition) classification standards. The minimal diagnostic workup must include morphological assessment and immunophenotyping to differentiate ALL from acute myeloid leukemia (AML). All patients shall undergo bone marrow aspiration plus at initial diagnosis. A definitive ALL diagnosis requires ≥20% blasts/immature lymphocytes in bone marrow (Note: Patients with \<20% blasts due to fever or pretreatment require comprehensive evaluation incorporating medical history and ancillary tests for differential diagnosis);
  3. Performance Status: 0-2

Exclusion criteria

Exclusion Criteria:

  1. Intracranial hemorrhage
  2. Pregnancy
  3. Psychiatric disorders or other conditions compromising protocol compliance
  4. Severe cardiac arrhythmia with abnormalities ( >500 ms)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Multicenter Study of Combined Chemotherapy and Transplantation for Adult ALL

    Drug: Induction Therapy Regimen · Drug: Pre-Treatment Regimen · Other: Post-CR Treatment · Drug: Post-CR Consolidation Regimens · Other: Transplant-Eligible Subsequent Therapy · Other: Allo-HSCT Protocol · Other: Non-Transplant Maintenance Therapy Options

Interventions

  • DrugInduction Therapy Regimen

    VICP+VEN regimen: * Vindesine: 3 mg/m²/day (max 4 mg), administered on days 1, 8, 15, 22. * Idarubicin (IDA): 8 mg/m², days 1, 8, 15, 22. * Cyclophosphamide (CTX): 500 mg/m², days 7, 21. * Prednisone: 1 mg/kg/day, days 1-14; 0.5 mg/kg/day, days 15-28 * Venetoclax (VEN) 8-day ramp-up: Day 1: 100 mg, Day 2: 200 mg, Days 3-8: 400 mg/day

  • DrugPre-Treatment Regimen

    Indications for pre-treatment: * WBC ≥30×10⁹/L, or significant hepatosplenomegaly/lymphadenopathy. * Laboratory signs of tumor lysis syndrome (e.g., electrolyte abnormalities). Pre-treatment protocol: * Glucocorticoids (e.g., prednisone or dexamethasone): Prednisone 1 mg/kg/day (PO/IV) for 3-5 days. * Optional addition of CTX: 200 mg/m²/day IV for 3-5 days.

  • OtherPost-CR Treatment

    Principles: 1. MRD-positive or rising: Administer blinatumomab (CD19/CD3 bispecific antibody) for residual disease clearance, followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT). 2. MRD-negative/unknown: Continue multi-agent chemotherapy ± blinatumomab consolidation. Allo-HSCT for patients with high-risk clinical/genetic features.

  • DrugPost-CR Consolidation Regimens

    ① Hyper-CVAD-B (Methotrexate/Cytarabine-based): * Methotrexate (MTX): 1 g/m² IV over 24h (Day 1) with urine alkalinization (pH \>7.0) and leucovorin rescue. * Cytarabine (Ara-C): 1 g/m² IV q12h (Days 2-3; total 4 doses). * Dexamethasone: 40 mg/day (PO/IV, Days 1-4). * Cycle interval: 21-28 days (alternating with other regimens). ② CAM Regimen: * CTX: 750 mg/m² IV (split over 2 days). * Ara-C: 75 mg/m²/dose (8 days; 1-2 doses/day IV; if once daily, administer 5 days/week × 2 weeks). * 6-MP: 50-75 mg/m²/day fasting (7-14 days PO).

  • OtherTransplant-Eligible Subsequent Therapy

    * Allo-HSCT for eligible patients after induction. * Conditioning regimen: TBI-VP16-CY. * Donor priority: HLA-matched sibling donor (MSD), Matched unrelated donor (MUD), Haploidentical donor (Haplo).(Consider age/donor health status).

  • OtherAllo-HSCT Protocol

    1.6.1 Conditioning Regimen (TBI-VP16-Cy/ATG): * TBI: 5 Gy (Days -7 to -6). * VP16: 10 mg/kg/day (Days -5 to -4). * CTX: 30 mg/kg/day (Days -3 to -2). * ATG: 7.5 mg/kg/day (Days -5 to -2). 1.6.2 GVHD Prophylaxis: * Basiliximab (anti-CD25 mAb): 50 mg (Days +1, +4). * Standard regimen: Cyclosporine (CsA): IV: 2 mg/kg/day (start Day -9; target level 150-250 μg/L). PO: 3-5 mg/kg/day BID (switch delayed until Day +10 if no aGVHD); Mycophenolate mofetil (MMF) + short-course methotrexate.

  • OtherNon-Transplant Maintenance Therapy Options

    ① Hyper-CVAD-B (Methotrexate/Cytarabine-based): * Methotrexate (MTX): 1 g/m² IV over 24h (Day 1) with urine alkalinization (pH \>7.0) and leucovorin rescue. * Cytarabine (Ara-C): 1 g/m² IV q12h (Days 2-3; total 4 doses). * Dexamethasone: 40 mg/day (PO/IV, Days 1-4). * Cycle interval: 21-28 days (alternating with other regimens). ② CAM Regimen: * CTX: 750 mg/m² IV (split over 2 days). * Ara-C: 75 mg/m²/dose (8 days; 1-2 doses/day IV; if once daily, administer 5 days/week × 2 weeks). * 6-MP: 50-75 mg/m²/day fasting (7-14 days PO). * Maintenance (6-MP/MTX alternating with V-Dex): 6-MP: 75 mg/m²/day at bedtime (Days 1-21); MTX: 20 mg/m² IM weekly × 3 weeks.\*Adjust doses to maintain WBC \~3×10⁹/L, ANC 1.0-1.5×10⁹/L.\*

06

What researchers measure

Primary outcomes

  1. Disease-free survival (DFS)

    Time frame: 24 months

  2. Complete remission (CR) rate

    Time frame: 24 months

  3. Partial remission (PR) rate

    Time frame: 24 months

  4. Non-remission (NR) rate

    Time frame: 24 months

  5. CR with incomplete hematologic recovery (CRi)

    Time frame: 24 months

Secondary outcomes

  1. Relapse rate

    Time frame: 24 months

  2. Treatment-related mortality(TRM)

    Time frame: 24 months

  3. Overall Survival(OS)

    Time frame: 24 months

  4. Event-Free Survival(EFS)

    Time frame: 24 months

  5. Adverse Event

    Time frame: 24 months

  6. Mortality

    Time frame: 24 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2025 (actual). Primary completion is estimated for Jun 2027, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2025
First posted
Jul 10, 2025
StartActual
Jun 1, 2025
Primary completionEst.
Jun 2027
CompletionEst.
Jul 2027
Last update
Jul 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07059156
Lead sponsor
Shanxi Bethune Hospital
Responsible party
Sponsor
First posted
Jul 10, 2025
Start date
Jun 1, 2025
Primary completion
Jun 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Jul 10, 2025

Study contacts

Tao Wang, Dr.
Contact
wangtao99699@163.com
13835175119

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion